Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of major adverse cardiovascular (CV) events and hospitalization for heart failure (HF) in patients with type 2 diabetes (T2D). Using CV MRI (CMR) and 31P-MRS in a longitudinal cohort study, we aimed to investigate the effects of the s...
Збережено в:
| Автори: | , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Англійська |
| Опубліковано: |
2021
|
| Онлайн доступ: | https://doi.org/10.2337/db21-0270 https://diabetesjournals.org/diabetes/article-pdf/70/12/2810/634595/db210270.pdf |
| Теги: |
Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|